Oleksandr Ekshyyan

1.1k total citations
25 papers, 883 citations indexed

About

Oleksandr Ekshyyan is a scholar working on Molecular Biology, Oncology and Otorhinolaryngology. According to data from OpenAlex, Oleksandr Ekshyyan has authored 25 papers receiving a total of 883 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Otorhinolaryngology. Recurrent topics in Oleksandr Ekshyyan's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Head and Neck Cancer Studies (4 papers) and Mitochondrial Function and Pathology (3 papers). Oleksandr Ekshyyan is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Head and Neck Cancer Studies (4 papers) and Mitochondrial Function and Pathology (3 papers). Oleksandr Ekshyyan collaborates with scholars based in United States, Japan and China. Oleksandr Ekshyyan's co-authors include Tak Yee Aw, Cherie‐Ann O. Nathan, Masahiro Okouchi, Xiaohua Rong, Tara Moore‐Medlin, Fleurette Abreo, John W. Fuseler, Lynn Harrison, Carol A. Rhoads and Gloria Caldito and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Oleksandr Ekshyyan

25 papers receiving 869 citations

Peers

Oleksandr Ekshyyan
Rui Ji China
A. Fujita Japan
Helen Lin United States
Liwei Liu China
Petrus R. de Jong United States
Attya Bhatti Pakistan
Oleksandr Ekshyyan
Citations per year, relative to Oleksandr Ekshyyan Oleksandr Ekshyyan (= 1×) peers Claudio Milanese

Countries citing papers authored by Oleksandr Ekshyyan

Since Specialization
Citations

This map shows the geographic impact of Oleksandr Ekshyyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oleksandr Ekshyyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oleksandr Ekshyyan more than expected).

Fields of papers citing papers by Oleksandr Ekshyyan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oleksandr Ekshyyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oleksandr Ekshyyan. The network helps show where Oleksandr Ekshyyan may publish in the future.

Co-authorship network of co-authors of Oleksandr Ekshyyan

This figure shows the co-authorship network connecting the top 25 collaborators of Oleksandr Ekshyyan. A scholar is included among the top collaborators of Oleksandr Ekshyyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oleksandr Ekshyyan. Oleksandr Ekshyyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mehta, Vikas, Tara Moore‐Medlin, José M. Flores, et al.. (2017). Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer. Oncotarget. 8(41). 70907–70915. 2 indexed citations
2.
Khandelwal, Alok R., Xiaohua Rong, Tara Moore‐Medlin, et al.. (2016). Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia. Cancer Prevention Research. 9(4). 296–304. 13 indexed citations
3.
Ekshyyan, Oleksandr, Alok R. Khandelwal, Xiaohua Rong, et al.. (2016). Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells.. PubMed. 8(11). 4822–4830. 18 indexed citations
4.
Anandharaj, Arunkumar, Oleksandr Ekshyyan, Yi Jia, et al.. (2015). EBV and not HPV sensitizes tobacco-associated head and neck cancer cell line FaDu to radiotherapy. Acta Oto-Laryngologica. 136(4). 354–362. 2 indexed citations
5.
Latimer, Brian, Oleksandr Ekshyyan, Tara Moore‐Medlin, et al.. (2015). Enhanced Systemic Bioavailability of Curcumin Through Transmucosal Administration of a Novel Microgranular Formulation.. PubMed. 35(12). 6411–8. 20 indexed citations
6.
Moore‐Medlin, Tara, Brian Latimer, Oleksandr Ekshyyan, et al.. (2015). Pharmacokinetics and bioavailability of a novel microgranular curcumin formulation in healthy volunteers versus head and neck cancer patients.. Journal of Clinical Oncology. 33(15_suppl). e12576–e12576. 1 indexed citations
7.
Moore‐Medlin, Tara, et al.. (2014). Serum Biomarkers in Head and Neck Squamous Cell Cancer. JAMA Otolaryngology–Head & Neck Surgery. 140(1). 5–5. 41 indexed citations
8.
Jiang, Ru, Oleksandr Ekshyyan, Tara Moore‐Medlin, et al.. (2014). Association between human papilloma virus/Epstein–Barr virus coinfection and oral carcinogenesis. Journal of Oral Pathology and Medicine. 44(1). 28–36. 73 indexed citations
9.
Anandharaj, Arunkumar, Oleksandr Ekshyyan, Xiaohua Rong, et al.. (2014). Abstract 3192A: Senescence may play an important role in explaining the mechanisms of increased radiosensitivity of HPV- and EBV-associated HNSCC. Cancer Research. 74(19_Supplement). 3192A–3192A. 1 indexed citations
10.
Moore‐Medlin, Tara, et al.. (2013). Curcumin Inhibits UV Radiation–Induced Skin Cancer in SKH‐1 Mice. Otolaryngology. 148(5). 797–803. 33 indexed citations
12.
Ekshyyan, Oleksandr, et al.. (2011). Efficacy and comparative effectiveness of sirolimus as an anticancer drug. The Laryngoscope. 121(5). 978–982. 12 indexed citations
13.
Ekshyyan, Oleksandr, Glenn Mills, Timothy Lian, et al.. (2010). Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced‐stage head and neck squamous cell carcinoma. Head & Neck. 32(12). 1619–1628. 25 indexed citations
14.
Clark, Cheryl, Oleksandr Ekshyyan, Fleurette Abreo, et al.. (2010). Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. The Laryngoscope. 120(6). 1159–1165. 46 indexed citations
15.
Ekshyyan, Oleksandr, Xiaohua Rong, Kavita M. Pattani, et al.. (2009). Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. 8(8). 2255–2265. 57 indexed citations
16.
Okouchi, Masahiro, et al.. (2007). Neuronal Apoptosis in Neurodegeneration. Antioxidants and Redox Signaling. 9(8). 1059–1096. 173 indexed citations
17.
Ekshyyan, Oleksandr & Tak Yee Aw. (2005). Decreased susceptibility of differentiated PC12 cells to oxidative challenge: relationship to cellular redox and expression of apoptotic protease activator factor-1. Cell Death and Differentiation. 12(8). 1066–1077. 47 indexed citations
18.
Ekshyyan, Oleksandr & Tak Yee Aw. (2004). Apoptosis: A Key in Neurodegenerative Disorders. Current Neurovascular Research. 1(4). 355–371. 88 indexed citations
19.
Ekshyyan, Oleksandr. (2004). Apoptosis in acute and chronic neurological disorders. Frontiers in bioscience. 9(1-3). 1567–1567. 58 indexed citations
20.
Ekshyyan, Oleksandr, et al.. (2003). Differential Effects of Superoxide Dismutase Isoform Expression on Hydroperoxide-induced Apoptosis in PC-12 Cells. Journal of Biological Chemistry. 278(15). 13294–13301. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026